Original article
Is the use of secukinumab after anti-TNF therapy greater than expected for the risk of developing inflammatory bowel disease?
El uso de secukinumab tras la terapia anti-TNF es mayor de lo esperado por el riesgo de desarrollar enfermedad inflamatoria intestinal?
Fatih Albayraka,
, Mustafa Gürb, Ahmet Karataşb, Süleyman Serdar Kocab, Bünyamin Kısacıkc
Autor para correspondencia
a Department of Internal Medicine, Division of Rheumatology, Dr. Ersin Arslan Training and Research Hospital, Şehitkamil, Gaziantep, Turkey
b Department of Internal Medicine, Division of Rheumatology, Fırat University Faculty of Medicine, Elazığ, Turkey
c Department of Rheumatology, Gaziantep Sanko Hospital, Şehitkamil, Gaziantep, Turkey
Leído
1045
Vecesse ha leído el artículo
394
Total PDF
651
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 7 | 0 | 3 | 3 |
| 2025 6 | 3 | 36 | 39 |
| 2025 5 | 73 | 43 | 116 |
| 2025 4 | 90 | 44 | 134 |
| 2025 3 | 67 | 29 | 96 |
| 2025 2 | 76 | 26 | 102 |
| 2025 1 | 85 | 45 | 130 |
| 2024 12 | 49 | 31 | 80 |
| 2024 11 | 69 | 63 | 132 |
| 2024 10 | 52 | 33 | 85 |
| 2024 9 | 60 | 27 | 87 |
| 2024 8 | 4 | 4 | 8 |
| 2024 6 | 3 | 2 | 5 |
| 2024 4 | 5 | 0 | 5 |
| 2024 3 | 12 | 7 | 19 |
| 2024 2 | 1 | 0 | 1 |
| 2024 1 | 1 | 0 | 1 |
| 2023 12 | 1 | 1 | 2 |
Mostrar todo
